Dupixent Quarterly Sales Surpass $6 Billion as COPD Indication Fuels Growth

Fueled by record sales of Dupixent, developed jointly with Sanofi, Regeneron posted its strongest quarterly performance since the COVID-19 pandemic.

According to Fierce Pharma, a U.S. biotechnology news outlet, on July 30 local time, Dupixent’s second-quarter global sales surged 38% from the same period a year earlier, surpassing $6 billion for the first time. This was the highest quarterly growth rate since the fourth quarter of 2022.

The explosive growth is attributed to the recent expansion of its indications, including U.S. Food and Drug Administration (FDA) approval as a treatment for chronic obstructive pulmonary disease (COPD). Dupixent is a monoclonal antibody therapy targeting IL-4/13.

Buoyed by strong Dupixent sales, Regeneron posted second-quarter earnings of $2.11 billion. That was $358 million above market analysts’ consensus estimate.

As a result, Regeneron’s total second-quarter sales increased 17%. This was the company’s strongest quarterly growth since the immunotherapy REGEN-COV surged in the market during the pandemic.

Regeneron CEO Len Schleifer said on a conference call, “Demand remains strong across all approved indications, and Dupixent still has substantial growth potential.” He added, “Market penetration in existing indications, expansion into new age groups and growth opportunities in overseas markets will drive growth.”

However, the company projected that Dupixent’s global sales growth would slow somewhat in the second half of the year. Marion McCourt, chief commercial officer, explained, “The effects of recently approved indications will be reflected in the full-year results, and there will be a base effect from the strong performance in the previous year.”

Meanwhile, Regeneron said it had fully repaid the remaining $3.1 billion in development costs owed to Sanofi. The payment was part of an amended agreement reached when Regeneron acquired all rights to the cancer drug Libtayo from Sanofi in 2022.

Chief Financial Officer Chris Fenimore said, “The contract amendment accelerated repayment of the remaining balance, temporarily reducing our share of collaboration revenue,” adding, “With repayment complete, our share of revenue under future collaboration agreements will increase.”